The anti-ITGB3 antibody conjugated liposomes are designed to selectively target melanoma cells expressing integrin β3 (ITGB3). This strategy enhances the delivery of chemotherapeutic agents directly to cancer cells, promoting localized treatment effects. Preclinical studies indicate that this approach can improve treatment response and reduce side effects. This targeted delivery mechanism holds potential for overcoming resistance to conventional therapies.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-785-sdAb | Recombinant Anti-human ITGB3 VHH Single Domain Antibody | FA, FC, ICC, ELISA | Llama VHH |
There are currently no Customer reviews or questions for VS-1024-FY187. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.